Scientists have discovered five subtypes of Alzheimer’s disease

The researchers believe that these findings may influence the upcoming development and administration of a drug for Alzheimer’s disease.

Scientists from the medical centers of the University of Amsterdam and Maastricht University in the Netherlands have identified five biological variants of Alzheimer’s disease. The results of the study were published in the journal Nature Aging Trusted Source.

Although it is not yet known how the disease occurs, scientists hope that their research will help influence how treatments are developed and prescribed in the future.

Dr Betty Times, associate professor of neurology, brain imaging and neurodegeneration at the University of Amsterdam Medical Centers and lead author of the study, said that she and her team decided to investigate biological processes other than beta -amyloid and tau protein that can also influence Alzheimer’s disease. .

“This is difficult to do because the human brain is not easily accessible. New methods have made it possible to measure many proteins in the cerebrospinal fluid, and the levels of these proteins provide a detailed picture of the process that takes place in the brain. So we used these changes to investigate whether certain subgroups of patients can be identified with Alzheimer’s disease with distinct underlying biology,” he said.

Scientists analyzed more than a thousand proteins in the cerebrospinal fluid of 419 people with Alzheimer’s disease and identified five biological variants of the disease:

• abnormal proliferation of nerve cells;

• innate immune activation;

• RNA (ribonucleic acid) dysregulation;

• damage to the choroid plexus of the brain;

• leakage of cerebrospinal fluid.

“The existence of these disease subtypes indicates that each may require different treatment. Upcoming trials should take this into account and test treatments in subtypes that match the mechanism of drug action. Additionally, every Alzheimer’s disease trial in the future should be subtype-specific to “It is possible to determine which of them respond best to treatment. Future trials should also take into account that the effects of drugs on different subtypes may differ,” explains Peter Jelle Visser, professor of molecular epidemiology of Alzheimer’s disease.

It should be remembered that Alzheimer’s disease is a progressive and incurable neurological disease that affects the brain and leads to a gradual deterioration of cognitive function and memory.

The main signs of Alzheimer’s disease include:

• Memory loss: gradual loss of short-term and long-term memory. A person may forget about important events, the names of loved ones and other previously learned facts.

• Cognitive impairment: decreased ability to solve simple problems, analyze and consider information.

• Changes in personal and social behavior: General effects on behavior, mood and social skills. The person may become impulsive, aggressive, or experience a greater loss of interest in social interaction.

• Physical changes: gradual effect on physical condition, in particular impairment of motor skills and coordination of movements.

• Loss of self-service: reduced ability to care for oneself.

It has previously been reported that viruses can cause inflammation and disrupt connections between the system that controls smell and parts of the brain associated with memory and learning, potentially speeding the onset of Alzheimer’s disease.

US approves drug for Alzheimer’s disease

New Correspondent.net on Telegram and WhatsApp. Subscribe to our channels Athletistic and WhatsApp